This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
27 Feb 2012

DSM Launches CYP Screening Platform

DSM Pharmaceutical Products has launched its Cytochrome P450 enzyme screening technology for the identification of metabolites through its InnoSyn route scouting services.

DSM Pharmaceutical Products has launched its Cytochrome P450 enzyme screening technology for the identification of metabolites through its InnoSyn route scouting services.

 

Cytochrome P450 enzymes (CYPs) belong to a super family of enzymes that have been identified in mammals, fungi and bacteria. They can be involved with drug metabolism and bioactivation in, for example, the human liver. Due to their potential toxic nature, the US FDA recommends that major metabolites derived from new therapeutics require additional characterisation and possible testing. CYPs may also generate novel bioactive molecules with improved characteristics compared with the parent molecule – and thus offer the possibility of accessing novel lead compounds.

 

Related News